ReviewDer Nervenarzt2015
[Neurobiology of schizophrenia: new findings from the structure to the molecules].
Review in Der Nervenarzt, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- [Update on anti-N-methyl-D-aspartate receptor encephalitis].Der Nervenarzt · 2018Review
- [German version of the Northoff catatonia rating scale (NCRS-dv) : A validated instrument for measuring catatonic symptoms].Der Nervenarzt · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During recent years improved methods in neuroimaging, molecular biology and genetics contributed to new insights into the neurobiology of schizophrenia. This review summarizes and discusses current findings and their impact on the pathophysiology of the disease. New magnetic resonance imaging (MRI) based methods allow investigation of small subregions of the hippocampus and structural and functional connectivity analyses using multimodal imaging approaches. Volume deficits are correlated with MRI spectroscopy based data of the glutamatergic and GABAergic systems and confirm the glutamate hypothesis of schizophrenia. Due to detailed clinical investigations, the association between brain imaging, symptom dimensions and cognitive deficits are becoming more evident. Genome-wide microarray assessments facilitate more detailed analyses of groups of differentially expressed genes and will advance with the application of next generation sequencing (NGS) and the development of inducible pluripotent stem cells. To date a multitude of new risk genes have been detected due to genome-wide association studies, each with a small effect. Future challenges encompass the identification of their neurobiological function and impact on neuroplastic processes, brain structure and function. Based on such information, the development of innovative risk-based therapy strategies is to be expected.
Indexed as
Identifiers
25123366What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.